Based on the extensive literature associating complement activation and cancer progression, we propose here that substantial clinical benefits can be achieved by multi-modal anticancer immunotherapies targeting both complement-mediated mechanisms (to reverse immunosuppression), and PD-1/PD-L1 immune checkpoints (to re-activate T-cell functionality). This evidence concerns the gene PDCD1 and cancer.